There are several immunomodulators under evaluation for COVID-19, including: colchicine; systemic and inhaled corticosteroids; fluvoxamine; granulocyte-macrophage colony-stimulating factor inhibitors; non-SARS-CoV-2 specific immunoglobulins; interleukin-1 inhibitors; interleukin-6 inhibitors; and kinase inhibitors. The gene discussed is CSF2; the disease is COVID-19.